saplin

WhiteOak Capital Pharma and Healthcare Fund

WhiteOak Capital Pharma and Healthcare Fund (Direct, Growth): saplin Score 8.5/10 (Strong) among 14 Sectoral/Thematic funds. 1Y return 26.3%, expense ratio 1.04%. Returns that beat most peers, but higher costs than most peers. NAV ₹18.37 on 11 Nov 2026.

Loading the full analysis…

Questions about WhiteOak Capital Pharma and Healthcare Fund

What is the expense ratio of WhiteOak Capital Pharma and Healthcare Fund?

The Direct plan's total expense ratio is 1.04% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages WhiteOak Capital Pharma and Healthcare Fund?

Ramesh Mantri (since 6 Feb 2024); Piyush Baranwal (since 6 Feb 2024); Dheeresh Pathak (since 6 Feb 2024); Ashish Agrawal (since 6 Jan 2025).

What are the top holdings of WhiteOak Capital Pharma and Healthcare Fund?

Divi's Laboratories 8.45%, Sun Pharmaceutical Industries 7.40%, Torrent Pharmaceuticals 6.78%, Apollo Hospitals Enterprise 4.73%, Laurus Labs 3.78% of the portfolio, as of 31 Aug 2026.

What returns has WhiteOak Capital Pharma and Healthcare Fund given?

1 year: 26.3% (category median 21.9%). Past returns do not predict future ones.

How big is WhiteOak Capital Pharma and Healthcare Fund?

About ₹858 cr (AMFI's average for the latest quarter).

How does WhiteOak Capital Pharma and Healthcare Fund score?

8.5 out of 10 (Strong) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.